Palantir Stock Rises on Q4 Strength, Defense Rally

Palantir stock rose after Q4 2025 results and FY2026 $7.2 billion revenue guidance, and an analyst upgrade drew trader flows amid defense tailwinds.

March 04, 2026·2 min read
View all news articles
Flat filled vector of a secure data vault with circuit lines symbolizing Palantir stock re-rating after Q4 results.

KEY TAKEAWAYS

  • Q4 2025 revenue grew 70.0% year over year, driven by accelerating U.S. commercial adoption.
  • FY2026 revenue guidance targets roughly $7.2 billion, implying about 61.0% YoY growth.
  • An analyst upgrade plus defense-sector momentum reinforced a re-rating narrative for Palantir stock.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Palantir stock rose on March 4, 2026, after the company reported Q4 2025 results and set FY2026 revenue guidance. The combination prompted an analyst upgrade and coincided with a defense-sector rally amid U.S.-Iran tensions.

Q4 Results and FY2026 Guidance

Palantir Technologies (PLTR) reported Q4 2025 revenue growth of 70% year over year and an adjusted operating margin of 57%, signaling expanding profitability. U.S. commercial revenue accelerated to 137% growth in the quarter, up from 121% in Q3 and 93% in Q2, reflecting rising adoption of the company’s AI platform.

The company generated $2.27 billion in free cash flow in FY2025, with a free-cash-flow margin of 51%, highlighting strong capital efficiency. Palantir’s FY2026 revenue guidance targets roughly $7.19–$7.2 billion, implying about 61% year-over-year growth. Management framed the year around profitability expansion and operating leverage.

Market Reaction and Defense Sector Momentum

On March 4, 2026, at least one analyst upgraded Palantir shares from Hold to Buy, citing the quarter’s strength and valuation compression. The analyst noted Palantir’s model-agnostic AI platform and deep Department of Defense integration. The stock rose 4.48% intraday.

This gain capped a five-day advance that lifted shares about 14%, adding roughly $44 billion in market value and bringing Palantir’s market capitalization to about $353 billion. The rally coincided with broader defense-sector strength and heightened U.S.-Iran tensions, which boosted investor interest in defense- and AI-exposed companies. The quarter’s results, guidance, and analyst upgrade reinforced a re-rating narrative focused on Palantir’s commercial growth and defense ties.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Netflix Earnings Send NFLX Stock Lower

Netflix Earnings Send NFLX Stock Lower

Netflix earnings for Q1 2026 beat forecasts but weak Q2 guidance and Reed Hastings' planned June exit pushed shares lower in after-hours trading.

Anthropic Mythos Rolls Out to Banks Amid Cyber Scrutiny

Anthropic Mythos Rolls Out to Banks Amid Cyber Scrutiny

Anthropic Mythos limited Glasswing rollout to banks prompted regulator scrutiny and raised cyber and operational risk, complicating bank positioning.

Spirit Airlines Liquidation Looms as Fuel Costs Surge

Spirit Airlines Liquidation Looms as Fuel Costs Surge

Spirit Airlines liquidation risk rises as jet fuel may exceed year-end cash, prompting creditors' doubts and forcing traders to reassess credit exposure.

AMD Stock Rises on Bernstein Raise and AI Demand

AMD Stock Rises on Bernstein Raise and AI Demand

AMD stock rose after Bernstein raised its 12-month target as record EPYC and MI300 data-center demand boosted flows ahead of May 5 Q1 2026 earnings.

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 Launches to General Availability

Anthropic Claude Opus 4.7 went general; pricing stayed unchanged and Mythos stayed gated, a setup that could shift cloud AI costs and investor positioning.

Abbott Earnings Beat After Exact Sciences Deal

Abbott Earnings Beat After Exact Sciences Deal

Abbott earnings posted revenue and adjusted-profit beats but narrowed FY EPS guidance after the Exact Sciences acquisition, likely pressuring shares.